Effect of Minocycline on Pain Caused by Nerve Damage (EMON)
Primary Purpose
Neuropathic Pain Caused by Lumbar Radicular Pain
Status
Completed
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
Minocycline
placebo
Amitriptyline
Sponsored by
About this trial
This is an interventional treatment trial for Neuropathic Pain Caused by Lumbar Radicular Pain
Eligibility Criteria
Inclusion Criteria:
Lumbar radicular pain due to disc herniation, failed back surgery syndrome or spinal canal stenosis causing neuropathic pain
Exclusion Criteria:
- Diabetic, alcoholic or drug induced polyneuropathies
- Depression or psychiatric comorbidity affecting pain sensation.
- Use of antidepressants
- Fibromyalgia and Chronic Fatigue Syndrome
- Pregnancy.
- Previous spinal cord damage
- Malignancies
- Allergy to minocycline or amitriptyline
Sites / Locations
- Ziekenhuis Oost-Limburg
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Arm Label
Placebo
Amitriptyline
Minocycline
Arm Description
Placebo, once daily
Amitriptyline 25mg, once daily
Minocycline 100mg, once daily
Outcomes
Primary Outcome Measures
Pain intensity
Pain intensity will be measured using a visual analogue scale and the change in pain intensity between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated
Secondary Outcome Measures
neuropathic pain diagnostic questionnaire (DN4) score
The DN4 questionnaire is used to assess the neuropathic symptoms of the pain and the change in DN4 score between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated
Amount of rescue medication taken
Rescue medication consists of tramadol 50mg by mouth 3-times daily if necessary. Patients will be provided with a total of 42 tablets of tramadol 50mg for the duration of the study. The remaining rescue medication will be counted on day 7 and day 14 and the change in rescue medication intake between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01869907
Brief Title
Effect of Minocycline on Pain Caused by Nerve Damage
Acronym
EMON
Official Title
Effect of Minocycline on Neuropathic Pain
Study Type
Interventional
2. Study Status
Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ziekenhuis Oost-Limburg
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine if minocycline is effective in the treatment of neuropathic pain. The effect of minocycline will be compared to the effect of placebo and amitriptyline.
Detailed Description
Neuropathic pain is pain caused by damage to the central or peripheral nervous system. To date, therapy consists of tricyclic antidepressants (such as amitriptyline) or anticonvulsants. However, results are disappointing. Minocycline, a FDA-approved second generation tetracycline, was efficacious in various animal models of neuropathic pain. We want to study the effect of minocycline in neuropathic pain in humans. The type of neuropathic pain we want to investigate is lumbar radicular pain since this is the most prevalent condition associated with neuropathic pain in humans.
This placebo-controlled randomized double blind trial consists of 3 arms:
Placebo, once daily by mouth during 14 days.
Amitriptyline 25mg, once daily by mouth during 14 days.
Minocycline 100mg, once daily by mouth during 14 days.
Patients can take rescue medication if necessary: tramadol 50mg by mouths up to 3-times daily.
Brain-derived neurotrophic factor is implicated in the generation and maintenance of neuropathic pain in different animal models of neuropathic pain. To study the role of brain-derived neurotrophic factor in neuropathic pain in humans, we will determine its concentration in serum and plasma before and after 14 days medication intake.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuropathic Pain Caused by Lumbar Radicular Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo, once daily
Arm Title
Amitriptyline
Arm Type
Active Comparator
Arm Description
Amitriptyline 25mg, once daily
Arm Title
Minocycline
Arm Type
Active Comparator
Arm Description
Minocycline 100mg, once daily
Intervention Type
Drug
Intervention Name(s)
Minocycline
Intervention Description
100 mg once daily by mouth during 14 days
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
once daily by mouth during 14 days
Intervention Type
Drug
Intervention Name(s)
Amitriptyline
Intervention Description
25mg once daily by mouth during 14 days
Primary Outcome Measure Information:
Title
Pain intensity
Description
Pain intensity will be measured using a visual analogue scale and the change in pain intensity between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated
Time Frame
Baseline (before start of study), 7 and 14 days after start of medication intake
Secondary Outcome Measure Information:
Title
neuropathic pain diagnostic questionnaire (DN4) score
Description
The DN4 questionnaire is used to assess the neuropathic symptoms of the pain and the change in DN4 score between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated
Time Frame
Baseline (before start of study), 7 and 14 days after medication intake
Title
Amount of rescue medication taken
Description
Rescue medication consists of tramadol 50mg by mouth 3-times daily if necessary. Patients will be provided with a total of 42 tablets of tramadol 50mg for the duration of the study. The remaining rescue medication will be counted on day 7 and day 14 and the change in rescue medication intake between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated
Time Frame
7 and 14 days after medication intake
Other Pre-specified Outcome Measures:
Title
Concentration of brain-derived neurotrophic factor (BDNF) in serum and plasma
Description
A blood sample (10ml) will be taken at baseline and after 14 days medication intake. The concentration of brain derived neurotrophic factor will be determined by high sensitivity ELISA (R&D systems® Europe, United Kingdom; detection range: 20-4,000 pg/ml) and the change in BDNF-concentration in serum and plasma between baseline and day 14 will be evaluated.
Time Frame
Baseline (before start of study) and after 14 days of medication intake.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Lumbar radicular pain due to disc herniation, failed back surgery syndrome or spinal canal stenosis causing neuropathic pain
Exclusion Criteria:
Diabetic, alcoholic or drug induced polyneuropathies
Depression or psychiatric comorbidity affecting pain sensation.
Use of antidepressants
Fibromyalgia and Chronic Fatigue Syndrome
Pregnancy.
Previous spinal cord damage
Malignancies
Allergy to minocycline or amitriptyline
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Van Zundert, MD, PhD
Organizational Affiliation
Ziekenhuis Oost-Limburg
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Martine Puylaert, MD
Organizational Affiliation
Ziekenhuis Oost-Limburg
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Pieter De Vooght, MD
Organizational Affiliation
Ziekenhuis Oost-Limburg
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Roel Mestrum, MD
Organizational Affiliation
Ziekenhuis Oost-Limburg
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
René Heylen, MD, PhD
Organizational Affiliation
Ziekenhuis Oost-Limburg
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Pascal Vanelderen, MD
Organizational Affiliation
Ziekenhuis Oost-Limburg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ziekenhuis Oost-Limburg
City
Genk
State/Province
Limburg
ZIP/Postal Code
3600
Country
Belgium
12. IPD Sharing Statement
Citations:
PubMed Identifier
23337936
Citation
Vanelderen P, Rouwette T, Kozicz T, Heylen R, Van Zundert J, Roubos EW, Vissers K. Effects of chronic administration of amitriptyline, gabapentin and minocycline on spinal brain-derived neurotrophic factor expression and neuropathic pain behavior in a rat chronic constriction injury model. Reg Anesth Pain Med. 2013 Mar-Apr;38(2):124-30. doi: 10.1097/AAP.0b013e31827d611b.
Results Reference
result
PubMed Identifier
22282331
Citation
Bastos LF, de Oliveira AC, Watkins LR, Moraes MF, Coelho MM. Tetracyclines and pain. Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):225-41. doi: 10.1007/s00210-012-0727-1. Epub 2012 Jan 27.
Results Reference
result
PubMed Identifier
19467572
Citation
Zhang Q, Peng L, Zhang D. Minocycline may attenuate postherpetic neuralgia. Med Hypotheses. 2009 Nov;73(5):744-5. doi: 10.1016/j.mehy.2009.04.028. Epub 2009 May 24.
Results Reference
result
PubMed Identifier
22685578
Citation
Sumracki NM, Hutchinson MR, Gentgall M, Briggs N, Williams DB, Rolan P. The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. PLoS One. 2012;7(6):e38525. doi: 10.1371/journal.pone.0038525. Epub 2012 Jun 7.
Results Reference
result
Learn more about this trial
Effect of Minocycline on Pain Caused by Nerve Damage
We'll reach out to this number within 24 hrs